The drug vemurafenib (Zelboraf) for metastatic melanoma in patients who test positive for the BRAF mutation, has been approved by the U.S. Food and Drug Administration. Vemurafenib, a BRAF-inhibitor, is a personalized investigational drug designed to specifically inhibit the activity of the mutant BRAF protein that is present in almost half of all melanoma cases, the most lethal and aggressive form of skin cancer. Jeffrey Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt said: "This is a great success story...
More...
More...